Lung Therapeutics is a biopharmaceutical company developing medicines for unmet medical needs in fibrosis and lung disease. Its two lead drug candidates are LTI-01, a pro-enzyme for the treatment of loculated pleural effusion (LPE), and LTI-03, a peptide drug targeting the survival of lung epithelial cells and the inhibition of the negative effects of fibroblast proliferation in idiopathic pulmonary fibrosis patients.
|HQ||Austin, TX, US||Map|
|Employees (est.) (Jul 2021)||15|
Lung Therapeutics total Funding
Lung Therapeutics latest funding size
Time since last funding
|2 years ago|
Lung Therapeutics investors
|Texas Venture Labs, UT Horizon Fund, Bios Partners|
When was Lung Therapeutics founded?
Lung Therapeutics was founded in 2013.
Who are Lung Therapeutics key executives?
Lung Therapeutics's key executives are Brian Windsor, Steven Idell and Charles Garner.
How many employees does Lung Therapeutics have?
Lung Therapeutics has 15 employees.
Who are Lung Therapeutics competitors?
Competitors of Lung Therapeutics include TFF Pharmaceuticals, Praedicare Labs and ReViral.
Where is Lung Therapeutics headquarters?
Lung Therapeutics headquarters is located at 2600 Vía Fortuna #360, Austin.
Where are Lung Therapeutics offices?
Lung Therapeutics has an office in Austin.
How many offices does Lung Therapeutics have?
Lung Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies